iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$14.71 USD
-0.27 (-1.77%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $14.69 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ITOS 14.71 -0.27(-1.77%)
Will ITOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ITOS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITOS
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
ITOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade
Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?
Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher
Other News for ITOS
Buy Rating Affirmed for iTeos Therapeutics on Strong Financials and Promising Pipeline Updates
ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q2 2024
iTeos Therapeutics GAAP EPS of -$0.18
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
iTeos Therapeutics reports Q2 EPS (96c), consensus ($1.04)